Pure Global
NCT01873352

Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation (ERADICATE--AF) Trial
Meshalkin Research Institute of Pathology of Circulation·Phase 3·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Fibrillation,Hypertension
Drug/Device/Intervention
catheter ablation
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Meshalkin Research Institute of Pathology of Circulation
Location
Short Hills,Novosibirsk, Russian Federation,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Jun 20, 2013
End date
Mar 01, 2019
Enrollment
302 participants
Primary outcome

AAD-free freedom from AF/atrial flutter/atrial tachycardia recurrence at least 30 seconds

Summary

The objective of this trial is to determine the role of renal sympathetic denervation in the
 prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a
 catheter-based AF ablation procedure is planned. Patients will be randomized to either AF
 catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01873352
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01873352 through Pure Global AI's free database. This Phase 3 trial is sponsored by Meshalkin Research Institute of Pathology of Circulation and is currently Completed. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 302 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.